Elan to sponsor Alzheimer's conference

ISEQ-listed biotechnology company Elan announced today that it is to be the main sponsor of the ninth International Conference on Alzheimer’s Disease and Related Disorders.

The conference will take place at the Pennsylvania Convention Center in Philadelphia from July 17 to 22.

New data from Elan's Alzheimer's research and development programs will be presented at the conference. The company will also host a symposium featuring leading Alzheimer's researchers from throughout the field.

“At Elan, our scientists are deeply committed to advancing the understanding of Alzheimer's and ultimately finding an effective treatment for this devastating disease,” said Dr Dale Schenk, Elan's Chief Scientific Officer.

'There has been immense progress in Alzheimer research in the last two decades,' said Sheldon Goldberg, President and CEO of the Alzheimer's Association, the organisers of the event.

Elan has been engaged in Alzheimer’s research for almost 20 years. It is estimated that 13 million people worldwide suffer from the disease.

At 12.30pm today, shares in Elan had risen 70c, or 4%, to €18.20 on the ISEQ exchange.